Zacks highlights research on Bank of America, Roche, Intuit, and microcap TSS, noting growth opportunities despite mixed industry trends.

This budget law is nothing but cruel. They threw billions at tax breaks for the wealthy without blinking, but keeping Arizonans with disabilities alive is too expensive.

The experimental CAR T-cell therapy treatment was given as part of a clinical trial that's enrolling adults with progressive ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis (MS), is calling for the provincial ...

Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...

Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and ...

Combining preconception, gestation, and postpartum periods, the total effect of pregnancy raised relapse rates (cRR 1.07, 95% ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.

Roche Holding AG is weighing direct-to-patient drug sales in the US, bypassing the middleman for its pricey medicines for ...